Aprobarbital: Difference between revisions
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| IUPAC_name | | Watchedfields = changed | ||
| verifiedrevid = 443395571 | |||
| image | | IUPAC_name = 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione | ||
| image = Aprobarbital.png | |||
| | | image2 = Aprobarbital_ball-and-stick_animation.gif | ||
<!--Clinical data--> | |||
| | | tradename = | ||
| | | Drugs.com = {{drugs.com|CONS|aprobarbital}} | ||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| | | pregnancy_category = | ||
| | | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | ||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | |||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | |||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | |||
| pregnancy_AU | | legal_status = | ||
| pregnancy_US | | routes_of_administration = | ||
| pregnancy_category= | |||
| legal_AU | <!--Pharmacokinetic data--> | ||
| legal_CA | | bioavailability = | ||
| legal_UK | | protein_bound = | ||
| legal_US | | metabolism = | ||
| legal_status | | elimination_half-life = | ||
| routes_of_administration = | | excretion = | ||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 77-02-1 | |||
| ATC_prefix = N05 | |||
| ATC_suffix = CA05 | |||
| PubChem = 6464 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = DB01352 | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 6221 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = Q0YKG9L6RF | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D00698 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 2791 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 7863 | |||
<!--Chemical data--> | |||
| C=10 | H=14 | N=2 | O=3 | |||
| molecular_weight = 210.23 g/mol | |||
| smiles = O=C1NC(=O)NC(=O)C1(C(C)C)C\C=C | |||
| InChI = 1/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15) | |||
| InChIKey = UORJNBVJVRLXMQ-UHFFFAOYAV | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15) | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = UORJNBVJVRLXMQ-UHFFFAOYSA-N | |||
| synonyms = aprobarbital, Oramon, allylpropymal, Alurate, 5-isopropyl- 5-allylbarbituric acid | |||
}} | |||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Aprobarbital''' (as known in the [[United States]], or '''aprobarbitone''' (as known elsewhere), sold as '''Oramon''', '''Somnifaine''', and '''Allonal''', is a [[barbiturate]] derivative invented in the 1920s by Ernst Preiswerk. It has [[sedative]], [[hypnotic]] and [[anticonvulsant]] properties, and was used primarily for the treatment of [[insomnia]].<ref> Reddemann H, Turk E. Oramon poisoning in infancy and childhood. Observations on 12 aprobarbital poisonings (German). Das Deutsche Gesundheitswesen. 1966 May 12;21(19):878-81. </ref> Aprobarbital was never as widely used as more common barbiturate derivatives such as [[phenobarbital]] and is now rarely prescribed as it has been replaced by newer drugs with a better safety margin. | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
{{ | {{Barbiturates}} | ||
{{Hypnotics and sedatives}} | |||
[[Category:Barbiturates]] | [[Category:Barbiturates]] | ||
[[Category: | [[Category:Alkenes]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 14:35, 13 April 2015
Clinical data | |
---|---|
Synonyms | aprobarbital, Oramon, allylpropymal, Alurate, 5-isopropyl- 5-allylbarbituric acid |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C10H14N2O3 |
Molar mass | 210.23 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Aprobarbital |
Articles |
---|
Most recent articles on Aprobarbital Most cited articles on Aprobarbital |
Media |
Powerpoint slides on Aprobarbital |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Aprobarbital at Clinical Trials.gov Clinical Trials on Aprobarbital at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Aprobarbital
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Aprobarbital Discussion groups on Aprobarbital Patient Handouts on Aprobarbital Directions to Hospitals Treating Aprobarbital Risk calculators and risk factors for Aprobarbital
|
Healthcare Provider Resources |
Causes & Risk Factors for Aprobarbital |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Aprobarbital (as known in the United States, or aprobarbitone (as known elsewhere), sold as Oramon, Somnifaine, and Allonal, is a barbiturate derivative invented in the 1920s by Ernst Preiswerk. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.[1] Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed as it has been replaced by newer drugs with a better safety margin.
References
- ↑ Reddemann H, Turk E. Oramon poisoning in infancy and childhood. Observations on 12 aprobarbital poisonings (German). Das Deutsche Gesundheitswesen. 1966 May 12;21(19):878-81.